Categories
Change Password!
Reset Password!
In RA patients with inadequate response to DMARDs or biologics the relative effectiveness and safety outcomes of tofacitinib and baricitinib were identified in this study.
This study reported that tofacitinib 10mg + MTX and
baricitinib 4mg + MTX were the most efficacious interventions for RA patients
with inappropriate response to DMARDs or biologics therapy. Also, they do not
showed significant SAEs. But, long-term studies are awaited in a large number
of patients with active RA that is inadequately responsive to MTX or biologics
to determine the relative efficacy and safety of tofacitinib and baricitinib.
In RA patients with
inadequate response to DMARDs or biologics the relative effectiveness and
safety outcomes of tofacitinib and baricitinib were identified in this study.
The Bayesian network meta-analysis was carried out and the
evidence from RCTs was combined to evaluate the safety and efficacy of
baricitinib and tofacitinib in combination with DMARDs in RA patients with an
inadequate DMARD or biologics.
It was found out that
as per ACR20 response the Tofacitinib 10 mg + methotrexate and baricitinib 4 mg
+ methotrexate was ranked the most efficacious for active RA with an inadequate
DMARD or biologic response. Then was the efficacy of baricitinib 2 mg +
methotrexate, tofacitinib 5 mg + methotrexate, and adalimumab + methotrexate.
There was no notable difference in the incidence of serious adverse events
after all the evaluated treatments.
In this analysis, it
was observed that tofacitinib 10 mg + MTX and baricitinib 4 mg + MTX were the
most effective treatments in active RA patients with an inadequate DMARD or
biologic response and have no significant risk of serious adverse events.
Zeitschrift für Rheumatologie
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
S.-C. Bae, Y. H. Lee
Comments (0)